Background/Objective: The effect of daily prenatal and postnatal vitamin supplementation on concentrations of breast milk nutrients is not well characterized in HIV-infected women. We examined the impact of vitamin supplementation during pregnancy and lactation on breast milk concentrations of retinol, carotenoids and tocopherols during the first year postpartum among 626 HIV-infected Tanzanian women. Subjects/Methods: We conducted a randomized, double-blind, placebo-controlled trial. Women were assigned to one of four daily oral supplements: vitamin A þ b-carotene (VA þ BC); multivitamins (MV; B, C and E); MV þ VA þ BC or placebo. Concentrations of breast milk nutrients were determined by high-performance liquid chromatography at birth and every 3 months thereafter. Results: Supplementation with VA þ BC increased concentrations of retinol, b-carotene and a-carotene at delivery by 4799, 1791 and 84 nmol l À1 , respectively, compared to no VA þ BC (all Po0.0001). MV supplementation did not increase concentrations of a-tocopherol or d-tocopherol at delivery but significantly decreased concentrations of breast milk g-tocopherol and retinol. Although concentrations of all nutrients decreased significantly by 3 months postpartum, retinol, a-carotene and b-carotene concentrations were significantly higher among those receiving VA þ BC at 3, 6 and 12 months compared to no VA þ BC. a-Tocopherol was significantly higher, while g-tocopherol concentrations were significantly lower, among women receiving MV compared to no MV at 3, 6 and 12 months postpartum. Conclusions: Sustained supplementation of HIV-infected breastfeeding mothers with MV could be a safe and effective intervention to improve vitamin E concentrations in breast milk. VA þ BC supplementation increases concentrations of breast milk retinol but it is not recommended in HIV-infected mothers due to the elevated risk of vertical transmission.
Introduction
Approximately 90% of the nearly 530 000 new HIV infections annually in children under 15 year are attributed to mother-to-child transmission (UNAIDS, 2006) . Among these 5-20% are transmitted during breastfeeding (Coutsoudis et al., 2004; Iliff et al., 2005) . Although total avoidance of breastfeeding eliminates the risk of transmission via breast milk, in many developing countries where HIV is a substantial public health burden this option often fails to meet the criteria of acceptability, feasibility, affordability, sustainability and safety (AFASS). In such circumstances, the World Health Organization (WHO) recommends that HIVinfected mothers exclusively breastfeed their infants for up to 6 months or until replacement feeding meets the criteria of AFASS (World Health Organization, 2006) .
In many regions of Africa, HIV infection coexists with malnutrition and the disease may further increase the nutrient requirements of mothers above those of normal pregnancy and lactation (Baum et al., 1997; Papathakis et al., 2007) . If the nutrient requirements of an HIV-infected mother are not met, the redistribution of specific nutrients from body stores to breast milk may be impaired and could contribute to the development of nutrient deficiencies among exclusively breastfed infants. We have previously reported that the prevalence of vitamins A, E and B12 deficiencies of breastfed infants born to unsupplemented HIV-infected women were high, between 12 and 29% . These high prevalences suggest that breast milk concentrations of these nutrients were insufficient to meet the infants' daily needs. Suboptimal vitamin status among breastfed infants born to unsupplemented HIV-infected women could result in increased incidence of diarrhea (Fawzi et al., 2003) and impaired immunity, growth and psychomotor development McGrath et al., 2006) .
It is unclear whether improving the micronutrient status of HIV-infected mothers through micronutrient supplementation increases the concentrations of these nutrients in milk. Although one study in Malawi suggested that prenatal vitamin A supplementation increased breast milk in the early postpartum period (Semba et al., 2000) , the effects of continued daily vitamin supplementation during pregnancy and throughout lactation on concentrations of vitamins in breast milk are not well known. We assessed the impact of daily vitamin supplementation during pregnancy and lactation on concentrations of retinol, b-carotene, a-carotene, a-tocopherol, g-tocopherol and d-tocopherol in breast milk from delivery through the first year postpartum in a randomized clinical trial conducted among HIV-infected Tanzanian women.
Methods
Study design and population From 1995 to 1997, 1078 HIV-infected pregnant women were enrolled in a clinical trial of vitamin supplements in relation to vertical transmission and HIV disease progression in Dar es Salaam, Tanzania. Details of the trial design have been reported elsewhere (Fawzi et al., 2002) . Briefly, eligible women between 12 and 27 weeks of gestation who consented to participate were randomly assigned to receive a daily oral dose of one of four regimens: (1) vitamin A and b-carotene (VA þ BC: 5000 IU (1500 mg retinol activity equivalents) of preformed vitamin A plus 30 mg of b-carotene), (2) multivitamins (MV) that did not include vitamin A and b-carotene (20 mg of thiamine, 20 mg of riboflavin, 25 mg of vitamin B6, 100 mg of niacin, 50 mg of vitamin B12, 500 mg of vitamin C (purified L-ascorbic acid), 30 mg of vitamin E (RRR-a-tocopherol acetate) and 0.8 mg of folic acid), (3) MV that included vitamin A and b-carotene (same doses as above), or (4) placebo. The supplements were administered from enrollment throughout pregnancy and continued after delivery. All women, irrespective of the assigned experimental regimen, were given daily doses of iron and folate, and weekly doses of chloroquine as antimalarial prophylaxis during pregnancy. We assessed compliance with the study regimen at every monthly clinic visit by counting the number of pills absent from the bottles provided at the previous visit. We then estimated the proportion of tablets absent from the returned bottles over the total number of tablets the individual should have taken. Compliance was high, 90% during pregnancy and 83% by 2 years from randomization. It was similar in all treatment arms.
In accordance with the guidelines of the WHO at the time of the study (UNICEF/UNAIDS/WHO, 1998) and the Tanzanian Ministry of Health, HIV-infected women were provided with information about the benefits and risks associated with infant feeding options; however, the decision on whether to breastfeed was ultimately made by the mother. Breastfeeding was adopted by 499% of participating women. At delivery and every 3 months thereafter, breast milk samples were collected by manual expression from either breast and stored at À70 1C.
Laboratory methods
Prior to nutrient extraction, 250 ml of a breast milk internal standard consisting of 1 mg of trans-b-Apo-8 0 -carotenal (Fluka) dissolved in 500 ml of ethanol (EtOH) was added to each 750 ml aliquot of breast milk sample. Samples were saponified twice in 750 ml EtOH, 500 ml of 20% ascorbic acid and 2 ml of 60% KOH, and incubated at 50 1C for 5 min between each saponification. Samples were twice extracted with 2 ml of hexane and water-washed. The hexane layer was evaporated under nitrogen for 15 min at 30 1C and reconstituted in 250 ml of a 3:1:1 mixture of acetonitrile:ethanol: dioxane.
The concentrations of retinol, total b-carotene, a-carotene, a-tocopherol, d-tocopherol and g-tocopherol were quantitated by high-performance liquid chromatography on a Restek Ultra C18 150 mm Â 4.6 mm column, 3 mm particle size encased in a water bath to prevent temperature fluctuations, and equipped with a trident guard cartridge system (Restek Corp., Bellefonte, PA, USA). The minimum detection limits in milk were 1.90, 1.65 and 3.12 nmol l À1 for a-carotene, b-carotene and retinol, respectively and 37.15, 40.71 and 67.78 nmol l À1 for g-, d-and a-tocopherol, respectively.
Statistical analyses
We examined the impact of vitamin supplements during pregnancy and lactation on the concentrations of breast milk retinol, carotenoids and tocopherols during the first year postpartum following the intent-to-treat principle. Curves of average nutrient concentrations over time were estimated using a mixed effects model (PROC MIXED; SAS Institute, Cary, NC, USA) with restricted cubic splines (Durrleman and Simon, 1989) . In these models, each nutrient was the outcome while predictors included linear and spline terms for time postpartum (in months), the treatment variable and interaction terms between the treatment and time variables. These mixed models used random effects for the intercept and the linear term for time, which accounted for the within-person correlation of measurements in the estimation of the variance. These methods do not require the same number of observations on each subject or that the measurements be obtained at exactly the same time intervals between or within individuals; therefore all available breast milk measures on all women were used. We tested for interactions between the two treatment arms using the likelihood ratio test. Given that there were no significant interactions between the MV alone and VA þ BC arms on any of the outcomes evaluated, we assessed the effect of VA þ BC by comparing regimens that included VA þ BC (groups 1 and 3) against regimens that did not include VA þ BC (groups 2 and 4). Similarly, the effect of MV was assessed by comparing MV-containing groups (2 and 3) against non-MV-containing groups (1 and 4). Treatment effects were estimated as the difference in concentrations between supplemented and unsupplemented women at delivery, and 3, 6 and 12 months postpartum. Confidence intervals were constructed using robust estimates of the variance (White, 1980) . The effects of supplementation did not differ after adjustment for total fat concentration of milk, thus results are presented unadjusted for fat content. Analyses were carried out with the Statistical Analyses System Software (SAS Institute). . Women were similar with respect to baseline characteristics by treatment arm ( Table 1) .
Ethical clearance
The concentrations of breast milk retinol, b-carotene and a-carotene decreased between 0 and 3 months postpartum irrespective of treatment arm. Despite these decreases, women who received VA þ BC had significantly higher concentrations of breast milk retinol, b-carotene and acarotene at all time points during the first year postpartum compared to women who did not receive VA þ BC (Table 2) . Supplementation with VA þ BC did not influence concentrations of a-, g-or d-tocopherol from delivery to 1 year postpartum (data not shown).
The concentrations of breast milk tocopherols also decreased significantly between 0 and 3 months postpartum. However, supplementation with MV during pregnancy and lactation resulted in significantly increased concentrations of a-tocopherol at 3, 6 and 12 months postpartum (Table 3) . MV supplementation significantly decreased concentrations of breast milk g-tocopherol at all time points and reduced retinol concentrations at delivery. MV supplementation was not associated with changes in concentrations of b-carotene, or a-carotene (data not shown). There were no significant interactions between the VA þ BC and the MV treatment arms on the concentrations of nutrients in breast milk (all PX0.10).
Discussion
In this study, daily prenatal and postnatal supplementation with VA þ BC to HIV-infected women doubled the concentrations of retinol in breast milk and increased the concentrations of b-carotene and a-carotene by approximately ninefold and threefold, respectively, during the first year postpartum. Daily supplementation with MV (vitamins B, C and E) increased a-tocopherol concentrations in breast milk by approximately 20% while MV supplementation was associated with a B25% reduction in breast milk concentrations of g-tocopherol. In the placebo group, the concentrations of retinol, b-carotene, a-carotene and the tocopherols were comparable to those reported from studies in nonsupplemented, presumably HIV-uninfected women at similar times postpartum (Gossage et al., 2002; Canfield et al., 2003; Schweigert et al., 2004; Sakurai et al., 2005) .
The magnitude of the effect of supplementation with either retinol or b-carotene on breast milk retinol concentrations has been highly variable as reported by nine randomized controlled trials in presumably HIV-uninfected women (Stoltzfus et al., 1993; Roy et 1999; Vinutha et al., 2000; Canfield et al., 2001; Muslimatun et al., 2001; Bahl et al., 2002; Basu et al., 2003; Dijkhuizen et al., 2004) and one randomized controlled trial in HIVinfected Malawian women (Semba et al., 2000) . This variation likely depends on differences in the dose and timing of supplementation. In our study, daily prenatal and postnatal supplementation with VA þ BC approximately doubled breast milk concentrations of retinol at all time points. The average magnitude of effect reported by other studies, in which the majority of vitamin A supplementation regimens were single, large doses provided in the early postpartum period, has been reported to be approximately 30% (minimum ¼ À37%, maximum ¼ 337%). In the majority of studies that used large doses administered once in the early postpartum period, increases in retinol concentrations were not sustained beyond 6 months (Rice et al., 1999; Bahl et al., 2002; Basu et al., 2003) . In our study, however, daily prenatal and postnatal supplementation with VA þ BC resulted in sustained increases in concentrations of breast milk retinol for up to 1 year postpartum. Mean7s.e. for nutrient concentrations and the mean (95% confidence interval) for the effect of treatment were estimated from cubic spline models. The effect of VA þ BC was estimated by comparing mothers who received VA þ BC (assigned to VA þ BC þ MV or VA þ BC without MV) vs mothers who did not receive VA þ BC (assigned to MV alone or placebo). Mean7s.e. for nutrient concentrations and the mean (95% confidence interval) for the effect of treatment were estimated from cubic spline models. The effect of MV was estimated by comparing mothers who received MV (assigned to VA þ BC þ MV or MV without VA þ BC) vs. mothers who did not receive MV (assigned to VA þ BC alone or placebo).
We found that VA þ BC supplementation increased concentrations of b-carotene in breast milk from delivery to 1 year postpartum. This finding is consistent with randomized controlled studies of single dose (Canfield et al., 1997) and daily b-carotene supplementation (Canfield et al., 1998 (Canfield et al., , 1999 (Canfield et al., , 2001 Rice et al., 1999; Dijkhuizen et al., 2004) as well as supplementation with b-carotene-rich red palm oil (Lietz et al., 2001 (Lietz et al., , 2006 . VA þ BC supplementation was also associated with sustained increases in breast milk a-carotene concentrations. These findings are comparable to those observed in supplementation studies in which daily b-carotene supplementation increased a-carotene concentrations in serum (Willett et al., 1983; Micozzi et al., 1992; Wahlqvist et al., 1994; Pappalardo et al., 1997) . It has been hypothesized that in populations with depressed antioxidant capacity, such as cancer and HIV patients, b-carotene supplementation preserves a-carotene concentrations by reducing its use in antioxidant activities (Pappalardo et al., 1997) .
Enhancing the concentrations of retinol in breast milk could improve the health outcomes of breastfeeding infants. It has been estimated that approximately 20% of supplemental vitamin A is transferred from the mother to the infant via breastfeeding (Ross and Harvey, 2003) . Two studies reported that single dose maternal vitamin A supplementation (200 000 IU of preformed retinol) during the early postpartum period reduced the incidence and duration of febrile illnesses, diarrheal diseases and respiratory illnesses (Roy et al., 1997; Basu et al., 2003) , and the incidence of measles (Basu et al., 2003) of breastfeeding infants up to 6 months postpartum. We had previously reported that VA þ BC supplementation of mothers during pregnancy and lactation increased serum retinol of breastfeeding infants at 6 weeks and 6 months of age . The observed increases in serum retinol could be the result of the effects of supplementation on retinol concentrations in breast milk as we currently report. Despite the ability of maternal VA þ BC supplementation to improve health outcomes in breastfeeding infants, supplementation with VA þ BC to HIV-infected women during pregnancy and lactation is not recommended due to the risk of increased mother-to-child transmission through breastfeeding (Fawzi et al., 2002) . Since the majority of women in African countries do not know their HIV status, the potential risks of unknowingly supplementing HIV-infected women with vitamin A and b-carotene need to be considered.
Multivitamins supplementation during pregnancy and lactation increased breast milk a-tocopherol concentrations from 3 to 12 months postpartum and decreased concentrations of g-tocopherol at all time points and of retinol at delivery. Although additional studies of the effects of vitamin E supplementation on tocopherol concentrations in breast milk were not available for comparison, the findings from our study are consistent with those from Baylin et al. (2005) who reported that MV supplementation was associated with increased serum vitamin E in breastfed infants at 6 weeks and 6 months of age and reduced serum retinol in infants at 6 weeks of age. Changes in nutrient concentrations with MV supplementation, including a decrease in retinol, might be attributed to the a-tocopherol content of the supplement. In well-nourished men, serum retinol concentrations were significantly decreased after 16 weeks of daily high-dose a-tocopherol supplementation (800 IU) (Willett et al., 1983) , consistent with our findings in breast milk. Other studies have also reported a negative impact of a-tocopherol supplementation on serum and adipose tissue concentrations of g-tocopherol (Handelman et al., 1985 (Handelman et al., , 1994 Traber and Kayden, 1989; Huang and Appel, 2003) , likely via competition during absorption and the promotion of metabolic degradation of g-tocopherol by high concentrations of a-tocopherol (Wolf, 2006) . Because g-tocopherol possess approximately one-third the antioxidant capacity of a-tocopherol (Bieri et al., 1976) , reductions in g-tocopherol that are accompanied by equivalent increases in a-tocopherol concentrations are unlikely to impair the total antioxidant capacity.
Additional studies in this population of HIV-infected mothers and their infants showed that daily prenatal and postnatal supplementation with vitamins B, C and E was associated with child health outcomes such as improved growth , increased CD4 cell counts, reduced risk of diarrhea (Fawzi et al., 2003) and improved psychosocial and motor development (McGrath et al., 2006) . Our present findings lend mechanistic support to these previous studies, in that the observed benefits on the infants' nutritional and health status could be mediated by increases in the concentration of nutrients in breast milk. Specifically, increased concentrations of vitamins in breast milk including a-tocopherol, B vitamins and vitamin C may have mediated improvements in child health outcomes.
Current infant guidelines recommend that in situations where replacement feeding options do not meet AFASS criteria, the infants of HIV-infected mothers should be exclusively breastfed for the first 6 months of life or until these criteria are met. Because supplementation with VA þ BC is associated with increased mother-to-child transmission, interventions that promote enhanced intakes of vitamin A to recommended levels by increasing overall dietary intakes and diversity rather than VA þ BC supplementation may be indicated in pregnant and lactating HIV-infected women. Daily prenatal and postnatal supplementation with vitamins E, C and B could be an effective and low-cost intervention to increase the concentrations of other micronutrients available to the infants through breastfeeding, and improve the health of breastfeeding infants born to HIV-infected mothers.
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